In 2012 UBC CPD received the Royal College Accredited CPD Provider Innovation Award for This Changed My Practice.
By Dr. Kevin Afra, Maggie Wong, PharmD, Tim T.Y. Lau, PharmD, and Dr. Victor Leung on August 15, 2022
Antibiotic treatment duration decision-making is fundamentally a balance of expected benefit and harm. Anchoring our expectations of benefit and harm with the most current literature can better inform clinical decision-making. The harms of antibiotics are often underappreciated. Shorter treatment durations are just as effective as longer durations for a wide range of common infections.
By Trana Hussaini Pharm D and Eric M. Yoshida MD FRCPC on November 13, 2019
For the first time, since the identification of hepatitis C virus, the goal of HCV elimination is a tangible and achievable target mainly due to the availability of highly efficacious and well tolerated DAA regimens.
By Dr. Alissa Wright on January 25, 2017
Canadians travel a lot and are increasingly traveling to more exotic and remote destinations. Unfortunately, travel does carry certain risks with respect to infection. Post-travel assessment of a febrile patient must be comprehensive, but completed in a timely manner so that patients get the care they need.
By Dr. Soren Gantt on June 8, 2016
Approximately 1 out of every 150 live-born infants has congenital CMV infection (cCMV). Of these, most are asymptomatic. However, more than 20% will suffer permanent neurologic sequelae, including hearing loss, intellectual disability, and visual deficits. In fact, cCMV is responsible for 25% of all childhood hearing loss, and is the second most common cause of intellectual disability after Down syndrome.